期刊
CLINICAL PHARMACOLOGY & THERAPEUTICS
卷 94, 期 2, 页码 207-210出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/clpt.2013.59
关键词
-
资金
- National Institutes of Health (NIH)/National Institute of General Medical Sciences Pharmacogenomics Research Network [U01 GM92666, U01 HL105198, GM61374, U01 GM92655, U19 HL065962, U19 GM61388, KL2 RR024151, U01 GM074492]
- NIH/National Cancer Institute [CA 36401, CA 21765]
- American Lebanese Syrian Associated Charities
The pace of discovery of potentially actionable pharmacogenetic variants has increased dramatically in recent years. However, the implementation of this new knowledge for individualized patient care has been slow. The Pharmacogenomics Research Network (PGRN) Translational Pharmacogenetics Program seeks to identify barriers and develop real-world solutions to implementation of evidence-based pharmacogenetic tests in diverse health-care settings. Dissemination of the resulting toolbox of implementation best practices will prove useful to a broad audience.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据